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Abstract 
 
Transforming Growth Factor-ß1 Accelerates Resorption of a 
Calcium Carbonate Biomaterial in Periodontal Defects 
 
Background: In a previous study, recombinant human TGF-ß1 (rhTGF-ß1) in a 
calcium carbonate carrier was implanted into critical-size, supraalveolar periodontal 
defects under conditions for guided tissue regeneration (GTR) to study whether 
rhTGF-ß1 would enhance or accelerate periodontal regeneration. The results showed 
minimal benefits of rhTGF-ß1 and a clear account for this could not be offered. One 
potential cause may be that the rhTGF-ß1 formulation was biologically inactive. 
Several growth or differentiation factors have been suggested to accelerate 
degradation of biomaterials used as carriers. The objective of this study was to 
evaluate possible activity of rhTGF-ß1 on biodegradation of the calcium carbonate 
carrier. 
Methods: rhTGF-ß1 in a putty-formulated particulate calcium carbonate carrier was 
implanted into critical-size, supraalveolar periodontal defects under conditions for 
GTR in five Beagle dogs. Contralateral defects received the calcium carbonate carrier 
combined with GTR without rhTGF-ß1 (control). The animals were euthanized at 
week 4 week postsurgery when block-biopsies of the defect sites were collected for 
histologic and histometric analysis. Radiographs were obtained at defect creation, 
week 2 and week 4. 
iv 
 
Results: No statistically significant differences were observed in new bone formation 
(bone height and area) among the treatments. However, total residual carrier was 
significantly reduced in sites receiving rhTGF-ß1 compared to control (p=0.04). 
Similarly, carrier density was considerably reduced in sites receiving rhTGF-ß1 
compared to control, the difference being borderline statistically significant (p=0.06). 
Conclusions: Within the limitations of the study, it may be concluded that rhTGF-ß1 
accelerates biodegradation of a particulate calcium carbonate biomaterial indicating a 
biologic activity of the rhTGF-ß1 formulation apparently not encompassing enhanced 
or accelerated periodontal regeneration. 
 
 
KEY WORDS 
Transforming growth factor- ß1, calcium carbonate carrier, biodegradation, 
periodontal regeneration. 
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Transforming Growth Factor-ß1 Accelerates 
Resorption of a Calcium Carbonate Biomaterial in 
Periodontal Defects 
 
Ki-Tae Koo, D.D.S., M.S.D. 
Department of Dental Science, Graduate School, Yonsei University 
(Directed by Prof. Chong-Kwan Kim, D.D.S., M.S.D., PhD.) 
 
I. Introduction 
Transforming growth factor-ß (TGF-ß) is a homodimeric peptide with multifunctional 
actions controlling growth, differentiation, and function of a broad range of target 
cells.1 Tissue-specific and developmentally dependent expression strongly suggests a 
significant role in specific morphogenetic and histogenetic events. Thus far, five 
distinct TGF-ßs with 65-80% homology have been identified.1 Currently thought to 
consist of at least 26 different proteins, TGF-ß1 supports wound healing by 
augmenting angiogenesis and fibroblast collagen formation.2,3 In addition, TGF-ß1 is 
thought to be involved in regulating cell proliferation and differentiation and the 
production of extracellular matrix.4 Also, a role of TGF-ß1 in recruiting and 
stimulating osteoprogenitor cells to proliferate, providing a pool of early osteoblasts 
has been suggested.5 In perspective, TGF-ß1 technologies appear attractive candidate 
therapies to support periodontal wound healing/regeneration. 
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In a previous study, recombinant human TGF-ß1 (rhTGF-ß1) in a putty-
formulated particulate calcium carbonate carrier was implanted into critical-size, 
supraalveolar periodontal defects under conditions for guided tissue regeneration 
(GTR) to study whether rhTGF-ß1* would enhance or accelerate periodontal wound 
healing/regeneration.6 Control sites received the calcium carbonate carrier combined 
with GTR without rhTGF-ß1. The histometric analysis could not discern significant 
benefits of the rhTGF-ß1 formulation. Overall, sites receiving rhTGF-ß1 and control 
treatments exhibited limited bone formation and regeneration of the periodontal 
attachment suggesting marginal, if any, effects of rhTGF-ß1. Although the results 
failed to discern a significant benefit of rhTGF-ß1, an obvious account of the results 
could not be offered. Could possibly the putty-formulated particulate calcium 
carbonate carrier or the GTR device rendered the growth factor ineffective or 
biologically inactive? Parallel studies evaluating rhTGF-ß1 using the supraalveolar 
periodontal defect model without GTR showed similar limited effects ruling out an 
inhibitory effect of the GTR device.7 Other studies suggest that biomaterials 
implanted into periodontal sites indeed may obstruct bone formation and periodontal 
regeneration.8 Still other studies may be interpreted to suggest that growth or 
differentiation factors may accelerate biodegradation/biotransformation of a 
biomaterial used as a carrier.9,10 
 
*  Genentech Inc., San Francisco, CA, USA 
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A re-examination of the study by Wikesjö et al.6 using additional parameters was thus 
deemed necessary to discern possible effects of rhTGF-ß1 on biodegradation of the 
putty-formulated particulate calcium carbonate carrier. 
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II. Materials and Methods 
A. Animals 
Five male Beagle dogs (age 18-24 months, weight 12-15 kg) were used. Animal 
selection, management, surgery protocol, and periodontal defect preparation followed 
routines approved by the local Institutional Animal Care and Use Committee. The 
animals were fed a soft-consistency laboratory diet supplemented with vitamins 
throughout the study. A soft diet was chosen to alleviate potential mechanical 
interference with wound healing during food intake. 
 
B. Surgical Protocol  
Surgical procedures were performed under sodium pentobarbital anesthesia† (20-30 
mg/kg, IV) preceded by acepromazine‡.(1 mg/kg, IM) Routine dental infiltration 
anesthesia was used at the surgical sites. During surgery, the animals received 
lactated Ringer's solution§. (300-500 mL, IV)  
Bilateral, critical-size, supraalveolar periodontal defects were created at the 3rd 
and 4th mandibular premolar teeth in each animal.11 Briefly, following sulcular 
incisions and elevation of buccal and lingual mucoperiosteal flaps, the alveolar bone 
was resected around the circumference of the teeth using chisels and water-cooled 
rotating burs.  
† Nembutal® Sodium Solution, Abbott Laboratories, North Chicago, IL, USA 
‡
 PromAce®, Aveco Co Inc., Fort Dodge, IA, USA 
§
 Lactated Ringer's Inj., USP, Abbott Laboratories 
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The exposed root surfaces were instrumented with curettes, chisels, and water-
cooled rotating diamonds to remove the cementum. The resulting clinical defect 
approximated 5 mm from the cemento-enamel junction (CEJ) to the reduced alveolar 
crest. The 1st and 2nd mandibular premolar teeth were extracted and the crown of the 
1st molar amputated level with the reduced alveolar crest. 
The maxillary 1st, 2nd, and 3rd premolar teeth were surgically extracted and the 
maxillary 4th premolars reduced in height and exposed pulpal tissues were sealed with 
Cavit®║ in order to alleviate potential trauma from the maxillary teeth to the 
experimental mandibular sites. 
 
C. Experimental Protocols 
Using a split-mouth design, contralateral, supraalveolar periodontal defects were 
implanted with rhTGF-ß1 in a carrier or carrier alone (control). Experimental 
treatments were alternated between left and right jaw quadrants in consecutive 
animals. Both treatments were combined with GTR. The carrier comprised medical 
grade, natural, porous, particulate calcium carbonate¶ and medical grade hydroxyethyl 
starch providing putty-like handling characteristics; 0.5% gelatin and 20 µM sodium 
acetate solution was mixed with hydroxyethyl starch to form a visco-elastic gel to 
contain the calcium carbonate particles in a manageable mass.  
║  Cavit®, ESPE, Seefeld/Oberbayern, Germany 
¶  Biocoral® 1000, Inoteb, Saint-Gonnery, France 
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For each defect scheduled to receive rhTGF-ß1, 0.25 mL buffer containing 20 µg 
rhTGF-ß1 was added to approximately 0.7 g calcium carbonate particles, the 
hydroxyethyl starch gel was then added to produce a homogenous putty-like mass. 
Final implant volume/defect approximated 0.8 mL. rhTGF-ß1 and control constructs 
were prepared under aseptic conditions. 
 
D. Wound Management 
Defects receiving rhTGF-ß1 or control treatments had the putty-like material shaped 
around the premolar teeth to the contour of the resected alveolar bone. The teeth were 
then fitted with an expanded polytetrafluoroethylene (ePTFE) barrier# secured with an 
ePTFE suture** at the CEJ (Figure 1). Periostea were fenestrated at the base of the 
mucoperiosteal flaps and the flaps were advanced, adapted, and sutured using 
horizontal mattress sutures approximately 2 mm coronal to the CEJ. 
 
E. Postsurgery Protocol 
A long-acting opioid†† (0.015 mg/kg IM, BID, 2 days) was used for immediate pain 
control.  
 
# GORE-TEX Regenerative Material Transgingival Configuration, W.L. Gore & 
Associates Inc., Flagstaff, AZ, USA 
** GORE-TEX Suture CV5, W.L. Gore & Associates Inc. 
†† Buprenex Injectable, buprenorphine HCl, Reckitt & Colman Pharmaceuticals Inc., 
Richmond, VA, USA 
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A broad-spectrum antibiotic‡‡ (2.5 mg/kg IM, BID, 2 weeks) was used for infection 
control Plaque control was maintained by twice daily topical application of 
chlorhexidine§§. (40 mL of a 2% solution) Observations of experimental sites with 
regards to gingival health, flap adaption, edema, and purulence were made daily. The 
ePTFE devices were not removed. 
Gingival sutures were removed at day 10. Photographs were obtained at defect 
creation, suture removal, and at week 2 and 4. Radiographs were obtained at defect 
induction, and at week 2 and 4. Thiopental sodium anesthesia║║ (20-25 mg/kg, IV) 
was used for suture removal and radiographic registrations. 
 
F. Histological Procedures 
The animals were euthanized at week 4 postsurgery using an intravenous injection of 
concentrated thiopental sodium. Tissue blocks including teeth, bone, and soft tissues 
were removed. The blocks were fixed in 10% buffered formalin for 3-5 days, 
decalcified in 5% formic acid for 8-10 weeks, trimmed, dehydrated, and embedded in 
butyl methacrylate-paraffin. Serial sections (7 µm) were cut in a buccal-lingual plane 
throughout the mesial-distal extension of the teeth.  
 
‡‡  Baytril® Brand of Enrofloxacin, Mobley Corporation, Shawnee, KS, USA 
§§  Chlorhexidine Gluconate 20%, ICI Pharmaceutical Group, Wilmington, DE, USA 
║║  Pentothal®, Abbott Laboratories, North Chicago, IL 
Every 14th section was stainedwith Ladewig’s connective tissue stain modified by 
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Mallory allowing for observations at 100-µm intervals. 
 
G. Histological Evaluation 
One experienced, calibrated, masked examiner (KTK) performed the histometric 
analysis using a PC-based image analysis system¶¶  with a custom application for the 
supraalveolar periodontal defect model.11 The most central stained section for each 
root of the 3rd and 4th premolars, identified by the size of the root canal, was used for 
the analysis.12 The following parameters were recorded for buccal and the lingual 
tooth surfaces for each section: 
Defect Height: distance between apical extension of the root planing and the CEJ. 
Device Height: distance between apical extension of the root planing and most 
coronal aspect of the ePTFE device. 
Defect Area: area under the ePTFE device circumscribed by the planed root, the 
width of the alveolar bone at apical extension of the root planing, and the 
device. 
Bone Regeneration (height): distance between apical extension of the root planing 
and the coronal extension of new alveolar bone formed along the planed root. 
Bone Regeneration (area): area represented by new alveolar bone formed along 
the planed root. 
 
¶¶  Image-Pro Plus™, Media Cybernetics®, Silver Spring, MD, USA 
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Total Residual Carrier: combined area of residual calcium carbonate carrier 
particles within the defect site. 
Carrier Density: ratio residual calcium carbonate carrier particles to bone within 
regenerated bone.  
 
H. Statistical Analysis 
Data was collected at tooth level and this was taken into consideration in the analysis. 
Standard errors of the mean were adjusted for the correlation of the observations 
within animals. Generalized estimating equations were used to assess the impact of 
different factors on carrier resorption. Measurements at tooth level were used and 
estimates were adjusted for the clustering of observations into animals using a robust 
variance estimator. Wald tests were used for multiple comparisons and the level of 
significance was set at 5%. A stratified analysis comparing residual carrier and new 
bone between the experimental groups was carried out using the median (5.1 mm2) of 
the wound area as cut off point. 
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III. Results 
 
A. Clinical Observations 
With the exception for one control site exhibiting gingival inflammation, the surgical 
sites exhibited healthy gingival conditions (Figure 1). There was no specific clinical 
characteristic differentiating rhTGF-ß1 sites from the control. Two animals 
demonstrated limited exposure of the ePTFE device. 
 
B. Radiographic Observations 
The radiographic appearance of the rhTGF-ß1 and control sites was similar reflecting 
the particulate nature of the calcium carbonate biomaterial. Radiopacity compatible 
with the biomaterial was observed in all animals suggesting that significant amounts 
remained at week 4 postsurgery. 
 
C. Histological Observations  
All defect sites were available for analysis with the exception for one root in a control 
site that was lost in the histotechnical preparation. Generally, the barrier device was 
located near the CEJ and the epithelium arrested at the CEJ. Three animals exhibited 
an inflammatory infiltrate, partially or completely occupying the defect site, localized 
to the buccal and/or lingual aspect of the mesial and/or distal root of the premolar 
teeth in sites receiving rhTGF-ß1. These animals also exhibited sites without an 
inflammatory infiltrate. Similarly, two control animals exhibited a bilateral 
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inflammatory infiltrate occupying the defect site. Defects in remaining animals did 
not exhibit an inflammatory infiltrate. 
Bone regeneration appeared limited to the apical aspect of the defect sites without 
notable differences between rhTGF-ß1 and control sites (Figure 2). However, one 
animal exhibited considerably greater bone formation for both the rhTGF-ß1 and 
control site. New cementum formation and regeneration of a functionally oriented 
periodontal ligament was limited, if at all appreciable, and thus not included in the 
histometric analysis. Similarly, root resorption appeared limited. Ankylosis was not 
observed. 
 
D. Histometric Analysis 
The rhTGF-ß1 and control groups did not differ significantly with regards to defect 
characteristics (defect height, device height and wound area; Table 1). There were 
also no statistically significant differences in bone formation (height and area) among 
the treatments. On the other hand, total residual carrier was significantly smaller in 
sites that received rhTGF-ß1 compared to that in the control (p=0.04). Similarly, 
carrier density was considerably smaller in the rhTGF-ß1 group; this difference 
however did not reach statistical significance (p=0.06). This observation may indicate 
that rhTGF-ß1 increased the resorption rate of the putty-formulated particulate 
calcium carbonate carrier, but this effect did not influence bone formation or 
regeneration of the periodontal attachment. 
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Table 1. Comparison between experimental groups (mean ± SE) 
 rhTGF-ß1 Control p-value 
Defect height (mm) 4.1 ± 0.2 4.3 ± 0.2 0.38 
Device height (mm) 4.1 ± 0.4 4.4 ± 0.1 0.89 
Wound area (mm2) 4.8 ± 0.6 5.5 ± 0.4 0.33 
Bone height (mm) 2.1 ± 0.2 2.2 ± 0.3 0.36 
Bone area (mm2) 3.2 ± 0.4 3.4 ± 0.5 0.81 
Residual carrier (mm2) 0.9 ± 0.2 1.6 ± 0.4 0.04 
Carrier density (%) 10.9 ± 2.2 15.7 ± 2.5 0.06 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
- 13 - 
 
A stratified analysis for wound area showed that carrier density and residual carrier 
area were significantly smaller for the rhTGF-ß1 group in smaller wound areas 
(p<0.05) (Figures 3 and 4). No significant differences were observed for these 
parameters in larger wound areas (p>0.05). No significant differences were observed 
between experimental groups regarding new bone height and area irrespective of 
wound area (Figures 5 and 6). 
In the multivariable model, residual carrier area was significantly smaller for the 
rhTGF-ß1 group, and this difference remained significant even after adjusting for 
wound and bone area (Table 2). On the other hand, no significant differences were 
observed in carrier density between experimental groups after adjusting for wound 
and bone area. Despite its positive effect on the resorption rate of the carrier, new 
bone height and area were not statistically different between groups, after adjusting 
for wound and carrier area (Table 3). 
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Table 2. Effect of rhTGF-ß1 on biodegradation after adjustment for wound and bone 
area. 
  ß ± SE p-value 
Residual carrier rhTGF-ß1 -0.51 ± 0.24 0.03 
 Wound area 0.24 ± 0.08 0.003 
 Bone area -0.07 ± 0.08 0.36 
    
Carrier density rhTGF-ß1 -1.16 ± 1.89 0.54 
 Wound area 1.79 ± 0.63 0.004 
 Bone area -0.50 ± 0.60 0.41 
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Table 3. Effect of rhTGF-ß1 on bone formation after adjustment for wound and 
carrier area. 
  ß ± SE p-value 
Bone height rhTGF-ß1 0.24 ± 0.25 0.33 
 Wound area 0.27 ± 0.08 0.0001 
 Carrier area 0.05 ± 0.14 0.74 
    
Bone area rhTGF-ß1 -0.02 ± 0.43 0.96 
 Wound area 0.50 ± 0.14 0.0001 
 Carrier area -0.27 ± 0.25 0.29 
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IV. Discussion 
The objective of this study was to evaluate the effect of rhTGF-ß1 on biodegradation 
of a putty-formulated particulate calcium carbonate biomaterial used as a carrier for 
rhTGF-ß1 in a well-characterized periodontal defect model. As previously observed, 
the rhTGF-ß1 construct, alone or combined with GTR, showed no significant effects 
on periodontal wound healing/regeneration6,7 potentially indicating the rhTGF-ß1 
formulation being biologically inactive. This study, on the other hand, also evaluating 
biodegradation of the calcium carbonate biomaterial, indicates that the rhTGF-ß1 
construct was biologically active accelerating degradation of the calcium carbonate 
biomaterial while not affecting periodontal wound healing/regeneration. 
Bone regeneration (height and area) was limited without significant differences 
between the rhTGF-ß1 and control groups. The reason for this may be attributed to 
obscure effects of rhTGF-ß1 combined with GTR or obstruction to bone formation by 
the calcium carbonate biomaterial obturating the defect site to migration and 
proliferation of a regenerate from the periodontal ligament. In previous studies, we 
also observed limited bone formation due to apparent obstruction of the wound space 
inflicted by biomaterials.8,14 
It is difficult to accept the limited effect of rhTGF-ß1 on bone formation in the 
periodontal model; several studies have confirmed an osteoconductive potential of 
rhTGF-ß1.5,15,16 Potentially GTR may compromise osteoconductive properties of 
rhTGF-ß1 or the 4-week healing interval may have been too short to reveal 
discernable effects of rhTGF-ß1; the cause may only be speculated upon. Nevertheless, 
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the amount of residual particulate carrier biomaterial was significantly smaller in the 
rhTGF-ß1 group compared to control in smaller wound areas. A stratified analysis 
dichotomizing the defect sites into smaller and larger wound areas showed that while 
bone formation (height and area) was not influenced by wound area, carrier density 
and residual carrier were significantly smaller for sites implanted with rhTGF-ß1 
while no difference was found in larger wound areas. This observation implies that 
rhTGF-ß1 increased the degradation rate of the biomaterial. This is in agreement with 
previous studies where differentiation factors such as bone morphogenetic proteins 
have been shown to accelerate degradation of the biomaterials used as carrier 
technologies.9,10  
Additional statistical analysis was performed to determine if any other factors 
affected the outcome. When the two treatment groups were compared adjusting for 
wound and bone area, residual carrier area was significantly smaller for the rhTGF-ß1 
group while carrier density was not affected even after adjusting for wound and bone 
area. New bone height and area were again not affected for both groups even after 
adjusting for wound and carrier area. 
Histometric analysis of new cementum formation, regeneration of a functionally 
oriented periodontal attachment, root resorption, ankylosis was not included. The 
histological observations revealed limited, if any, new cementum formation. Root 
resorption and ankylosis were rare. These observations are in synchrony with 
previous studies evaluating GTR technologies and using a 4-week healing interval.17 
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Tissue maturation in this defect model apparently commands longer observation 
intervals that regeneration of the periodontal attachment is clearly distinguishable at 
least using incandescent and polarized light microscopy.18  
Within the limitations of the study, it may be concluded that rhTGF-ß1 accelerates 
biodegradation of the particulate calcium carbonate biomaterial indicating a biologic 
activity of the rhTGF-ß1 formulation apparently not encompassing enhanced or 
accelerated periodontal regeneration. This observation corroborates a previous study 
where recombinant human bone morphogenetic protein-2 accelerated biodegradation 
of a biomaterial used as a carrier in the supraalveolar periodontal defect model also 
without affecting regeneration of the periodontal attachment.9  
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V.Conclusion 
In a previous study, recombinant human TGF-ß1 (rhTGF-ß1) in a putty-formulated 
particulate calcium carbonate carrier was implanted into critical-size, supraalveolar 
periodontal defects under conditions for guided tissue regeneration (GTR) to study 
whether rhTGF-ß1* would enhance or accelerate periodontal wound 
healing/regeneration.6 Control sites received the calcium carbonate carrier combined 
with GTR without rhTGF-ß1. The histometric analysis could not discern significant 
benefits of the rhTGF-ß1 formulation. Overall, sites receiving rhTGF-ß1 and control 
treatments exhibited limited bone formation and regeneration of the periodontal 
attachment suggesting marginal, if any, effects of rhTGF-ß1. Although the results 
failed to discern a significant benefit of rhTGF-ß1, an obvious account of the results 
could not be offered. The present study re-evaluated the previous study utilizing the 
same parameters to examine if this finding holds true and additional parameters were 
added to discern any possible effects of rhTGF-ß1 on biodegradation of the putty-
formulated particulate calcium carbonate carrier. The following conclustions were 
made. 
 
1. Bone regeneration (height and area) was limited without significant differences 
between the rhTGF-ß1 and control groups. 
 
2.  The amount of residual particulate carrier biomaterial was significantly smaller in 
the rhTGF-ß1 group compared to control in smaller wound areas. 
 
3.  Histological observations revealed limited, if any, new cementum formation. 
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Root resorption and ankylosis were rare findings. 
 
4.  It may be concluded that rhTGF-ß1 accelerates biodegradation of the particulate 
calcium carbonate biomaterial indicating a biologic activity of the rhTGF-ß1 
formulation apparently not encompassing enhanced or acclerated periodontal 
regeneration.  
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Figure Legends 
Figure 1. Critical-size, supraalveolar periodontal defect implanted with rhTGF-ß1 in a 
putty-formulated particulate calcium carbonate carrier before and after application of 
an ePTFE-barrier for GTR and at 4 weeks postsurgery (left). 
 
Figure 2. Photomicrographs showing the critical-size, supraalveolar periodontal 
defects at 4 weeks postsurgery. The left photomicrograph shows a defect site 
implanted with rhTGF-ß1 in the calcium carbonate carrier under conditions for GTR 
and the right photomicrographs shows a control defect without rhTGF-ß1. The green 
arrows delineate the base of the approximately 5-mm defects; the ePTFE-barriers 
adapted to the teeth at the CEJ. 
 
Figure 3. Carrier density by wound area (* p<0.05). Note significantly smaller carrier 
density for the rhTGF-ß1 group in the smaller wound areas. 
 
Figure 4. Residual carrier area by wound area (* p<0.05). Note significantly smaller 
carrier area for the rhTGF-ß1 group in the smaller wound areas. 
 
Figure 5. Bone height by wound area. No significant differences were observed 
between the two groups regarding new bone height irrespective of the wound areas. 
 
Figure 6. Bone area by wound area. No significant differences were observed 
between the two groups regarding new bone area irrespective of the wound areas. 
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Figure 1. Critical-size, supraalveolar periodontal defect implanted with rhTGF-ß1 in a 
putty-formulated particulate calcium carbonate carrier before and after application of 
an ePTFE-barrier for GTR and at 4 weeks postsurgery (left). 
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Figure 2. Photomicrographs showing the critical-size, supraalveolar periodontal 
defects at 4 weeks postsurgery. The left photomicrograph shows a defect site 
implanted with rhTGF-ß1 in the calcium carbonate carrier under conditions for GTR 
and the right photomicrographs shows a control defect without rhTGF-ß1. The green 
arrows delineate the base of the approximately 5-mm defects; the ePTFE-barriers 
adapted to the teeth at the CEJ. 
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Figure 3. Carrier density by wound area (* p<0.05). Note significantly smaller carrier 
density for the rhTGF-ß1 group in the smaller wound areas. 
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Figure 4. Residual carrier area by wound area (* p<0.05). Note significantly smaller 
carrier area for the rhTGF-ß1 group in the smaller wound areas. 
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Figure 5. Bone height by wound area. No significant differences were observed 
between the two groups regarding new bone height irrespective of the wound areas. 
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Figure 6. Bone area by wound area. No significant differences were observed 
between the two groups regarding new bone area irrespective of the wound areas. 
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국문 요약 
 변환 성장 유도 단백질인 Tranforming growth factor-ß1은 다양한 종류의 
세포들의 성장, 분화, 및 세포 기질의 생성에 관여한다고 알려져 왔다. 또, 
골모 세포들의 초기 생성에도 Tranforming growth factor-ß1 단백질이 활발하
게 관여한다고 보고된 바 있어 TGF- ß1을 사용한 치주조직치유나 재생 실
험들이 많이 진행되고 있다. 예전의 실험에서, Tranforming growth factor- ß1을 
calcium carbonate 운반체를 이용하여 상치조 결손부에 적용한 후 차폐막으
로 덮고 골 형성에 어떤 영향을 미치는지 실험하였다. 대조군(control group)
에서는 TGF-ß1을 적용하지 않은 채 Biocoral 운반체와 차폐막만 사용하였다. 
결과를 살펴보면 두 실험 군 간에 새롭게 생성된 골의 양이나 수직적인 높
이에 있어서 유의성 있는 차이가 없었다. 이는 TGF- ß1이 본 상치조 결손
부에서 치주조직재생에 부가적인 영향이 없는 것으로 해석될 수 있으나 몇
가지 의문점을 남기게 되었다. 본 연구에서는 이러한 의문점 중 TGF-ß1이 
운반체로서 사용된 calcium carbonate (Biocoral)이라는 재료에 미치는 영향에 
대하여 조사하기 위해 새로운 조직계측학적 기준들을 첨가하여 실험을 재
실시 하였다. 
새롭게 생성된 골의 양 (area)과 수직적인 높이 (height)는 두 실험 군 
간에 유의성 있는 차이가 없었고, 새로 생성된 백악질은 극히 제한적이었
다. 잔존하는 운반체 (calcium carbonate)의 양을 비교해보았을 때, rhTFG-ß1
군에서 운반체의 양이 현저히 감소됨을 관찰할 수 있었다. 결론적으로 
rhTFG-ß1이 calcium carbonate 운반체를 일련의 생물학적인 반응을 통하여 
흡수시킬 수 있다는 사실이 입증되었고, 이를 더 넓은 의미로 해석한다면 
치주조직재생에 사용되는 여러 성장인자들이 운반체로 사용되는 생물학적 
물질들에 영향을 미칠 수 있다는 결론을 내릴 수 있겠다. 
 
핵심되는 말 
변환성장유도 단백질 (Transforming growth factor Beta-1); 운반체 (calcium 
carbonate carrier); 생물학적 흡수 (biodegradation). 
 
